Parra-Machuca MG, Puente-Barragán AC, Ancona-Vadillo AE, Ruiz-Gastelum ED, Vásquez-Ortiz ZY, Sierra-Galán LM, Nuriulú-Escobar PL, Rosas-Munive E, García-Jiménez Y, Figueiras-Graillet LM

Idioma: Inglés [English version]
Referencias bibliográficas: 194
Paginas: 76-103
Archivo PDF: 467.36 Kb.

RESUMEN

La enfermedad cardiovascular es la primera causa de muerte en la mujer que sobrevive al cáncer de mama. La magnitud de los efectos cardiotóxicos depende no sólo del tratamiento antineoplásico, sino de la susceptibilidad individual, que está determinada por la enfermedad cardiovascular preexistente y los factores de riesgo concurrentes, así como de las intervenciones en la prevención, identificación y tratamiento oportuno de la cardiotoxicidad. La Asociación Nacional de Cardiólogos de México, inmersa en esta realidad, comparte en el presente documento un abordaje que explica la interacción de las dos entidades desde la perspectiva de la mujer de alto riesgo y resume las estrategias de detección y cardioprotección actuales.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Instituto Nacional de Geografía e Informática (INEGI) 2018. Disponible en: https://www.inegi.org.mx/sistemas/olap/consulta/general_ver4/MDXQueryDatos.asp?c=11144.

2. NIH surveillance, epidemiology and end result program. Cancer statistics review 1975-2016. Available in: https://seer.cancer.gov/csr/1975_2016/.

3. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2015; 34: 611-635.

4. Lara-Esqueda A, Meaney-Mendiolea E, Ceballos-Reyes GM, Asbun-Bojalil J, Ocharán-Hernández ME, Núñez-Sánchez M et al. Factores de riesgo cardiovascular en población femenina urbana de México. El estudio FRIMEX IIa. Rev Mex Cardiol. 2007; 18 (1): 24-34.

5. Mulrooney DA, Yeazel MW, Kawashima T et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009; 339: b4606.

6. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007; 25 (25): 3808-3815.

7. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011; 13 (3): R64.

8. Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016; 27 (1): 6-13.

9. Buttros DA, Branco MT, Orsatti CL, Almeida-Filho BS, Nahas-Neto J, Nahas E. High risk for cardiovascular disease in postmenopausal breast cancer survivors. Menopause. 2019; 26 (9): 2014-10304.

10. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Comparative risk assessment collaborating group (cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005; 366 (9499): 1784-1793.

11. Grajales Pérez EG, Cazares Flores C, Díaz Amezquita L, De Alba Ramírez V. Factores de riesgo para el cáncer de mama en México revisión de estudios en poblaciones mexicanas y México-americanas. Revista CES Salud Pública. 2014; 2 (5): 50-58.

12. Barish R, Lynce F, Unger K, Barac A. Management of cardiovascular disease in women with breast cancer. Circulation. 2019; 139: 1110-1120.

13. Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE et al. Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials. Clin Oncol. 2018; 36: 2710-2717.

14. Cárdenas-Sánchez J, Bargalló-Rocha JE, Piña VB y cols. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Gaceta Mexicana de Oncología. 2019; 16 (91): 1-170.

15. García M, Mulvagh SL, Merz CNB, Buring JE, Manson JE. Cardiovascular disease in women. Circulation Research. 2016; 118 (8): 1273-1293.

16. Mehta LS, Watson KE, Barac A et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018; 137 (8): e30-e66.

17. Arnett DK, Blumenthal RS, Albert MA. ACC/AHA Guideline on the primary prevention of cardiovascular disease: executive summary. Circulation. 2019; 140 (11): E596-E646.

18. Brandhorst S, Longo VD. Dietary restrictions and nutrition in the prevention and treatment of cardiovascular disease. Circ Res. 2019; 124 (6): 952-965.

19. Cicco PD, Catani MV, Gasperi V, Sibilano M, Quaglietta M, Savini I. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence. Nutrients. 2019; 11 (7): 1514-1542.

20. Seller A, Chen MA, Brown RL, Fagundez CP. Obesity, dietary factors, nutrition, and breast cancer risk. Curr Breast Cancer Rep. 2018; 10 (1): 14-27.

21. Schlesinger S, Chan DS, Vingeliene S et al. Carbohydrates, glycemic index, glycemic load, and breast cancer risk: a systematic review and dose–response meta-analysis of prospective studies. Nutrition Reviews. 2017; 75 (6): 420-441.

22. Zheng Y, Li Y, Satija A et al. Association of changes in red meat consumption with total and cause specific mortality among US women and men: two prospective cohort studies. BMJ. 2019; 365: 2110.

23. Sieri S, Chiodini P, Agnoli C et al. Consuming a high-fat diet is associated with increased risk of certain types of BC. JNCI Journal of the National Cancer Institutse. 2014; 106 (5): 1-6.

24. Katzmarzyk PT, Church TS, Craig CL, Bouchard C. Sitting time and mortality from all causes, cardiovascular disease, and cancer. Med Sci Sports Exerc. 2009; 41: 998-1005.

25. Hamah Levy T, Cuevas Nasu L, Rivera Dommarco J y cols. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. México: Instituto Nacional de Salud Pública; 2016. Disponible en; http://promocion.salud.gob.mx/dgps/descargas1/doctos_2016/ensanut_mc_2016-310oct.pdf.

26. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-952.

27. Chomistek AK, Manson JE, Stefanick ML, Lu B, Sands-Lincoln M, Going SB, Garcia L et al. Relationship of sedentary behavior and physical activity to incident cardiovascular disease: results from the Women’s Health Initiative. J Am Coll Cardiol. 2013; 61: 2346-2354.

28. Zhou Y, Zhao H, Peng C. Association of sedentary behavior with the risk of breast cancer in women: update meta-analysis of observational studies. Ann Epidemiol. 2015; 25: 687-697.

29. Armstrong MEG, Green J, Reeves GK, Beral V, Cairns BJ. Frequent physical activity may not reduce vascular disease risk as much as moderate activity: large prospective study of women in the united kingdom. Circulation. 2013; 131 (8): 721-729.

30. Rey-Vargas L, Sanabria-Salas MC, Fejerman L, Serrano-Gómez SJ. Risk factors for triple-negative breast cancer among Latina Women. Cancer Epidemiology Biomarkers & Prevention. 2019; 28 (11): 1771-1783.

31. Lanas F, Avezum A, Bautista LE et al. Risk factors for acute myocardial infarction in Latin America. Circulation. 2007; 115 (9): 1067-1074.

32. Lopez-Jimenez F, Corte-Bergoder M. Obesidad y corazón. Rev Esp Cardiol. 2011; 64 (2): 140-149.

33. Mortillo S, Filion KB, Genest J et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56: 1113-1132.

34. Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA: A Cancer Journal for Clinicians. 2017; 67 (5): 378-397.

35. Comisión Nacional contra las Adicciones. Encuesta Global de Tabaquismo en Adultos México 2015. 2a ed. México: Secretaría de Salud; 2016. http://omextad.salud.gob.mx/contenidos/encuestas/gats2015/ENCUESTA_GATS__2015.pdf.

36. Parada H, Bradshaw PT, Steck SE et al. Postdiagnosis changes in cigarette smoking and survival following breast cancer. JNCI Cancer Spectrum. 2017; 1 (1): 1-8.

37. Jacobs DR, Adachi H, Mulder I et al. Cigarette smoking and mortality risk: twenty-five year follow-up of the seven countries study. Arch Intern Med. 1999; 159 (7): 733-740.

38. Castelli WP. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke. Am J Obstet Gynecol. 1999; 180: S349-S56.

39. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003; 290: 86-97.

40. Jones ME, Schoemaker MJ, Wright LB, Ashworth A, Swerdlow AJ. Smoking and risk of breast cancer in the Generations Study cohort. Breast Cancer Research. 2017; 19 (1): 110.

41. Mosca L, Benjamin EJ, Berra K et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation. 2011; 123: 1243-1262.

42. Knott CS, Coombs N, Stamatakis E, Biddulph JP. All-cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population-based cohorts. BMJ. 2015; 350: h384.

43. Djousse L, Lee I-M, Buring J, Gaziano M. Alcohol consumption and risk of cardiovascular disease in women. Circulation. 2009; 120: 237-244.

44. Roerecke M, Rehm J. The cardioprotective association of average alcohol consumption and ischaemic heart disease: a systematic review and meta-analysis. Addiction. 2012; 107: 1246-1260.

45. Liu Y, Nguyen N, Colditz G. Links between alcohol consumption and breast cancer: a look at the evidence. Womens Health. 2015; 11 (1): 65-77.

46. Sarrel PM, Lufkin EG, Oursler MJ. Estrogen actions in arteries, bone and brain. Sci Med. 1994; 1: 44-53.

47. Writing Group for The Women’s Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Womens Health Initiative Randomized Controlled Trial. JAMA: The Journal of the American Medical Association. 2002; 288 (3): 321-333.

48. Schenck-Gustafsson K, Brincat M, Erel CT. EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas. 2011; 68: 94-97.

49. LaCroix AZ, Chlebowski RT, Manson JE et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011; 305: 1305-1314.

50. Collaborative Group of Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394: 1159-1168.

51. Pateras I, Giaginis C, Tsigris C et al. NF-kappa B signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links. Expert Opin Ther Targets. 2014; 18: 1089-1101.

52. Vink A, Schoneveld AH, Lamers D et al. HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis.. 2007; 195: e69-75.

53. Mendoza-Torres E, Bravo-Sagua R, Mónica Villa M et al. Enfermedades cardiovasculares y cáncer: ¿dos entidades mutuamente relacionadas? Rev Chil Cardiol. 2019; 38: 54-63.

54. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007; 121: 2373-2380.

55. Fang H, Placencio VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. Journal of the National Cancer Institute. 2012; 104: 1470-1484.

56. Cabarcas SM, Hurt EM, Farrar WL. Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease. Curr Mol Med. 2010; 10: 744-755.

57. Masoudkabir F, Sarrafzadegan N, Gotay C et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017; 263: 343-351.

58. Korniluk A, Koper O, Kemona H et al. From inflammation to cancer. Ir J Med Sci. 2017; 186: 57-62.

59. Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Rad Biol Med. 2012; 52: 2013-2037.

60. Colotta F, Allavena P, Sica A et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; 30: 1073-1081.

61. Wu Y, Antony S, Meitzler JL et al. Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett. 2014; 345: 164-173.

62. Hursting SD y Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol. 2012; 32: 1766-1770.

63. Ando S, Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol. 2011; 8: 263-275.

64. Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications. Arch Med Res. 2017; 48: 12-26.

65. DeBoer RA, Meijers WC, van der Meer P et al. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019; 21: 1515-1525.

66. Sanders JL, Chattopadhyay N, Kifor O et al. Ca(2þ)-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells. Am J Physiol Endrocrinol Metab. 2001; 281: E1267eE1274.

67. Swinnen JV, Beckers A, Brusselmans K et al. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Research. 2005; 65: 2441-2448.

68. Li J, Jiang P, Robinson M et al. AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis. 2003; 24: 827-834.

69. Xiang X, Saha AK, Wen R et al. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321: 161-167.

70. Motoshima H, Goldstein BJ, Igata M et al. AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol. 2006; 574: 63-71.

71. Wang W, Guan KL. AMP-activated protein kinase and cancer. Acta Physiologica (Oxford, England). 2009; 196: 55-63.

72. Maffuz-Aziz A, Labastida-Almendaro S, Sherwell-Cabello S, Ruvalcaba LE, Domínguez-Reyes CA, Tenorio-Torres JA et al. Supervivencia de pacientes con cáncer de mama. Análisis por factores pronóstico, clínicos y patológicos. Ginecol Obstet Mex. 2016; 84 (8): 498-506.

73. Riihima M, Thomsen H, Brandt A, Sundquist J, Hemminki K. Death causes in breast cancer patients. Ann Oncol. 2012; 23: 604-610.

74. Encuesta Nacional de Salud y Nutrición 2006. ISBN: 978-970-9874-33-4. https://www.insp.mx/produccion-editorial/publicaciones-anteriores-2010/658-resultados-de-nutricion-de-la-ensanut-2006.html1.Instituto Nacional de Geografía e Informática (INEGI) 2018.

75. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Franco A, Olaiz G, Rull JA, Sepúlveda J. El síndrome metabólico: un concepto en evolución. Gac Méd Méx. 2004; 140 (s2): S41-48.

76. Zamorano JL, Lancellotti P, Rodriguez MD, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur J Heart Fail. 2016; 19 (1): 9-42.

77. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020; 31 (2): 171-190.

78. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62: e147-e239.

79. Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J et al. The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 2020. Online ahead of print.

80. Plana JC. Chemotherapy and the Heart. Rev Esp Cardiol. 2011; 64 (5): 409-415.

81. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Col Cardiol. 2010; 55: 213-220.

82. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society European journal of heart failure, 10.1002/ejhf.1920. Advance online publication.

83. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. May Clin Pro. 2014; 89 (9): 1287-1306.

84. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy M. Cardiac toxicity 4 to20 years after completing anthracycline therapy. JAMA. 1991; 266: 1672-1677.

85. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja JC. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017; 389 (10075): 1195-1205.

86. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004; 13: 173-183.

87. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20: 1215-1221.

88. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. Ca Cancer J Clin. 2016; 66: 309-325.

89. Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015; 94: 228-237.

90. Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer. 2014; 50: 2162-2170.

91. Sungyub L, Chamberlain RS. Hypertension risk among cancer patients treated with sunitinib: a meta-analysis and systematic review [serial online]. Targeted Oncol. targetedonc.com/publications/targetedtherapies-cancer/2015/June-2015/Hypertension-Risk-Among-Cancer-Patients-Treated-With-Sunitinib-A-Meta-analysis-and-Systematic-Review.

92. Darby SC, Ewertz M, McGale P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368: 987-998.

93. Lee MS, Finch W, Mahmud E. Cardiovascular complications of radiotherapy. Am J Cardiol. 2013; 112: 1688-1696.

94. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366: 2087-2106.

95. Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J et al. Early Breast Cancer Trialists’ Collaborative Group. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017; 35: 1641-1649.

96. Darby S, Ewertz M, Hall P. Ischemic heart disease after breast cancer radiotherapy. N Engl J Med. 2013; 368: 2527.

97. Taylor CW, Wang Z, Macaulay E, Jagsi R, Duane F, Darby SC. Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003 to 2013. Int J Radiat Oncol Biol Phys. 2015; 93: 845-853.

98. Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018; 8: 145-152.

99. Bartlett FR, Colgan RM, Donovan EM, McNair HA, Carr K, Evans PM et al. The UK Heart Spare Study (Stage IB): randomized comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiother Oncol. 2015; 114: 66-72.

100. Woldmark N. Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery. Clinicaltrials.gov. Bethesda, MD: National Library of Medicine. Aug 2008. Identifier NCT01872975. https://clinicaltrials.gov/ct2/show/NCT01872975.

101. MacDonald SM. Proton Therapy for Breast Cancer: Getting to the Heart of the Matter. Int J Radiat Oncol Biol Phys. 2016; 95: 46-48.

102. Armstrong GT, Plana JC, Zhang N et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012; 30 (23): 2876-2884.

103. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014; 15 (10): 1063-1093.

104. Shaw LJ, Bairey Merz C N, Pepine C J, Reis SE, Bittner V, Kelsey S et al. Insights From the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol. 2006; 47 (3): S4-S20.

105. Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol. 2016; 34 (10): 1122-1130.

106. Law W, Johnson C, Rushton M, Dent S. The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population. Curr Oncol. 2017; 24 (5): 348.

107. D Angostino RB, Vasan RS, Pencia MJ et al. General Cardiovascular risk profile for user primary care the Framingham heart study. Circulation. 2008; 117: 743-753. https://reference.medscape.com/calculator/framingham-cardiovascular-disease-risk.

108. Alcocer LA, Lozada O, Fanghänel G, Sánchez-Reyes L, Campos-Franco E. Estratificación del riesgo cardiovascular global. Comparación de los métodos Framingham y SCORE en población mexicana del estudio PRIT. Cir Cir. 2011; 79: 168-174.

109. Ridker PM, Buring JE, Rifai N, & Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. JAMA. 2007; 297 (6): 611. https://www.mdcalc.com/reynolds-risk-score-cardiovascular-risk-women.

110. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017; 357: j2099. https://qrisk.org/three/index.php.

111. O’Brian PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology. 2008; 245 (3): 206-218.

112. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109: 2749-2754.

113. Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Tochukwu M, Edward TH et al. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2017; 70 (20): 2536-2551.

114. Germanakis I, Anagnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer. 2008; 51: 327-333.

115. Suzuki T, Hayashi D, Yamazaki T et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998; 136: 362-363.

116. Van Boxtel W, Bulten BF, Mavinkurve-Groothuis AM, Bellersen L, Mandigers CM, Joosten LA et al. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers. 2015; 20: 143-148.

117. Nousiainen T, Vanninen E, Jantunen E et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002; 251: 228-234.

118. Meinardi MT, van Veldhuisen DJ, Gietema JA et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol. 2001; 19: 2746-2753.

119. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 2015; 61: 1164-1172.

120. Plana JC, Thavendiranathan P, Bucciarelli D, Lancelloti P. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC Cardiovasc Imaging. 2018; 11 (8): 1173-1186.

121. Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol. 2013; 20: 443-464.

122. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 2000; 21: 1387-1396.

123. Armenian SH, Lacchetti C, Barac A , Carver J, Constine LS, Denduluri N. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2017; 35: 893-911.

124. Thavendiranathan P, Grant AD, Negishi T et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013; 8: 77-84.

125. Seraphim A, Westwood M, Bhuva AN et al. Advanced imaging modalities to monitor for cardiotoxicity. Curr Treat Options Oncol. 2019; 8: 9-73.

126. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013; 26: 493-498.

127. Saha SK, Kiotsekoglou A, Toole RS et al. Value of two-dimensional speckle tracking and real time three-dimensional echocardiography for the identification of subclinical left ventricular dysfunction in patients referred for routine echocardiography. Echocardiography. 2012; 29: 588-597.

128. Avi VM, Lang RM. Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy? J Am Col Cardiol. 2013; 61: 85-87.

129. Tang Q, Jiang Y, Xu Y, Xia H. Speckle tracking echocardiography predicts early subclinical anthracycline cardiotoxicity in patients with breast cancer. J Clin Ultrasound. 2017; 45: 222-230.

130. Narayan HK, French B, Khan AM et al. Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction. J Am Coll Cardiol Img. 2016; 9: 1131-1141.

131. Liu J, Banchs J, Mousavi N, Plana JC, Scherrer-Crosbie M, Thavendiranathan P et al. Contemporary role of echocardiography for clinical decision making in patients during and after cancer therapy. JACC Cardiovasc Imaging. 2018;11 (8): 1122-1131.

132. Toufan M, Pourafkari L, Ghahremani Nasab L, Esfahani A, Sanaat Z, Nikanfar A et al. Two-dimensional strain echocardiography for detection of cardiotoxicity in breast cancer patients undergoing chemotherapy. J Cardiovasc Thorac Res. 2017; 9: 29-34.

133. Doherty JU, Kort S, Mehran R et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. J Am Soc Echocardiogr. 2019; 32 (5): 553-579.

134. Hamo C E, Bloom MW, Cardinale D, Ky B, Nohria A, Baer L, Butler J. Cancer therapy–related cardiac dysfunction and heart failure. Cir Heart Fail. 2016; 9 (2): 1-10.

135. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2013; 26: 1013-1032.

136. Jolly M-P, Jordan JH, Melendez GC, McNeal GR, D’Agostino RBJ, Hundley WG. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J Cardiovasc Magn Reson. 2017; 19 (1): 59.

137. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003; 10: 132-139.

138. Raymond R. Russell, Jonathan Alexander, Diwakar Jain, Indu G. Poornima Ajay V. Srivastava, Eugene Storozynsky, and Ronald G. Schwartz. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol. 2016; 23 (4): 856-884.

139. Van Kriekinge SD, Berman DS, Germano G. Automatic quantification of left ventricular ejection fraction from gated blood pool SPECT. J Nucl Cardiol. 1999; 6: 498-506.

140. Marks L, Yu X, Prosnitz R, Zhou SM, Hardenbergh P, Blazing M et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005; 63: 214-223.

141. Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Netok S, Chareonthaitawee P et al. Clinical quantification of myocardial blood flow using PET: joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Cardiol. 2018; 25: 269-297. doi: 10.1007/s12350-017-1110-x.

142. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97: 2869-2879.

143. Eschenhagen T, Force T, Ewer M et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011; 13: 1-10.

144. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity challenges and opportunities. J Am Coll Cardiol. 2014; 64: 938-945.

145. Hourdequin JC, Schpero WL, McKenna DR, Piazik BL, Larson RJ. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann Oncol. 2013; 24: 2952-2962.

146. Legha SS, Benjamin RS, Mackay B et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982; 96: 133139.

147. Mao Z, Shen K, Zhu L, Xu M, Yu F, Xue D et al. Comparisons of cardiotoxicity and efficacy of anthracycline-based therapies in breast cancer: a network meta-analysis of randomized clinical trials. Oncol Res Treat. 2019; 42 (7-8): 405-413.

148. Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009; 27: 1177-1183.

149. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol. 2004; 31: 161-181.

150. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010; 17: CD005006.

151. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E; TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002; 94: 25-36.

152. Russell SD, Blackwell KL, Lawrence J, Pippen JE, Roe MT, Wood F et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy; a combined review of cardiac data from the National Surgical Adjuvant breas tan Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials J Clin Oncol- 2010; 28: 3416-3421.

153. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013; 49: 2900-2909.

154. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev- 2011; 6: CD003917.

155. Marty M, Espié M, Llombart A, Monnier A, Rapoport BL, Stahalova V; Dexrazoxane Study Group. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006; 17: 614-622.

156. Testore F, Milanese S, Ceste M, de Conciliis E, Parello G, Lanfranco C et al. Cardioprotective Effect of Dexrazoxane in Patients with Breast Cancer Treated with Anthracyclines in Adjuvant Setting. Am J Cardiovasc Drugs. 2008; 8: 257-263.

157. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009; 27: 127-145.

158. European Medicines Agency. Questions and answers on the review of dexrazoxane-containing medicines, powder for solution for infusion, 500 mg. Outcome of a procedure under Article 31 of Directive 2001/83/EC as amended. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Dexrazoxane_31/WC500108011.pdf.

159. Vaduganathan M, Hirji SA, Qamar A et al. Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. JACC Cardio Oncology. 2019; 1 (1): 54-65.

160. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy–induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114 (23): 2474-2481.

161. Janbabai G, Nabati M, Faghihinia M et al. Effect of enalapril on preventing anthracycline- induced cardiomyopathy. Cardiovasc Toxicol. 2017; 17: 130-139.

162. Gulati G, Heck SL, Ree AH et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016; 37 (21): 1671-1680.

163. Guglin M, Krischer J, Tamura R et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019; 73 (22): 2859-2868.

164. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Jr et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018; 71: 2281-2290.

165. Barbosa RR, Bourguignon TB, Torres LD et al. Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers. Rev Assoc Med Bras. 2018; 64 (8): 745-754.

166. Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2017; 104 (12): 971-977.

167. Kaya MG, Ozkan M, Gunebakmaz O et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013; 167: 2306-2310.

168. Kwan ML, Habel LA, 1Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008; 109: 573-57.

169. Acar Z, Kale A, Turgut M et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011; 58: 988-989.

170. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012; 60: 2384-2390.

171. Schupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis. 2008; 199: 278-287.

172. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2016 update: a report from the American Heart Association [published correction appears in Circulation. 2016;133:e599]. Circulation. 2015; 133: e38-e360.

173. Williams B, Mancia G, Spiering W et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018; 36 (12): 2284-2309.

174. Mach F, Baigent C, Catpano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019; 00: 1-78.

175. American Diabetes Association. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41(Supplement 1): S55-S64.

176. Eckel RH, Jakicic JM, Ard JD et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2960-2984.

177. Rock CL, Doyle C, Demark-Wahnefried W, et al: Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012; 62: 242-274.

178. Chlebowski RT, Blackburn GL, Thomson CA, et al: Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006; 98: 1767-1776.

179. Pierce JP, Natarajan L, Caan BJ et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: The Women’s Healthy Eating and Living (WHEL) randomized trial. JAMA. 2007; 298: 289-298.

180. Demark-Wahnefried W, Rogers LQ, Alfano CM et al. Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin. 2015; 65: 167-189.

181. Fung TT, Hu FB, Hankinson SE, Willett WC, Holmes MD. Low-carbohydrate diets, dietary approaches to stop hypertension-style diets, and the risk of postmenopausal breast cancer. Am J Epidemiol. 2011; 174: 652-660.

182. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, et al; on behalf of the American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010; 121: 586-613.

183. Irwin ML, McTiernan A, Manson JE et al. Physical activity and survival in postmenopausal women with breast cancer: Results from the Women’s Health Initiative. Cancer Prev Res (Phila). 2011; 4: 522-529.

184. Vrieling A, Buck K, Seibold P et al. Dietary patterns and survival in German postmenopausal breast cancer survivors. Br J Cancer. 2013; 108: 188-192.

185. Zheng JS, Hu XJ, Zhao YM, Yang J, Li D. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ. 2013; 346: f3706.

186. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V et al. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens, part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009; 10: 1033-1034.

187. Baan R, Straif K, Grosse Y et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007; 8: 292-293.

188. Baan DE, Jarman DW, Rehm J et al. Alcohol-attributable cancer deaths and years of potential life lost in the United States. Am J Public Health. 2013; 103: 641-648.

189. Casas R, Castro-Barquero S, Estruch R, Sacanella E. Nutrition and cardiovascular health. Int J Mol Sci. 2018; 19 (12): 3988-4019.

190. Sánchez, E. Life’s Simple 7: vital but not easy. J Am Heart Assoc. 2018; 7 (11): 1-4.

191. Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014; 63: 2985-3023.

192. Kwan ML, Kushi LH, Weltzien E et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: The life after cancer epidemiology study. J Clin Oncol. 1020; 28: 4410-4416.

193. Ibrahim EM, Al-Homaidh A. Physical activity, and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol. 2011; 28: 753-765.

194. Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 2014; 25: 1293-1311.